Author, as appears in the article.: Curran A; Rull A; Navarro J; Vidal-González J; Martin-Castillo M; Burgos J; Falcó V; Ribera E; Torrella A; Planas B; Peraire J; Crespo M

Department: Medicina i Cirurgia

URV's Author/s: Peraire Forner, José Joaquin / RULL AIXA, ANNA

Keywords: Treatment-naive System Switch Risk Rilpivirine Nafld Mortality Lipidomics Hiv Fatty-liver-disease Efavirenz Cardiovascular-disease Adults

Abstract: HIV and antiretroviral therapy affect lipidmetabolism. Lipidomics quantifies several individual species that are overlooked using conventional biochemical analyses, outperforming traditional risk equations. We aimed to compare the plasma lipidomic profile of HIV patients taking efavirenz (EFV) or rilpivirine (RPV). Patients >= 18 years old on EFV co-formulated with emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) with HIV-RNA < 50 copies/mL for >= 6 months were randomized to continue EFV/FTC/TDF (n = 14) or switch to RPV/FTC/TDF (n =15). Lipidomic analyses conducted by mass spectrometry (MS) were performed at baseline and after 12 and 24 weeks. OWLiver (R) Care and OWLiver (R) tests were performed to estimate the presence of fatty liver disease (NAFLD). No significant differences (83% male, median age 44 years, 6 years receiving EFV/FTC/TDF, CD4(+) count 740 cells/mm(3), TC 207 [57 HDL-C/133 LDL-C] mg/dL, TG 117 mg/dL) were observed between the groups at baseline. Significant reductions in plasma lipids and lipoproteins but increased circulating bilirubin concentrations were observed in patients who switched to RPV/FTC/TDF. Patients on RPV/FTC/TDF showed a decrease in the global amount of storage lipids (-0.137 log(2) [fold-change] EFV vs. 0.059 log(2) [fold-change] RPV) but an increase in lysophosphatidylcholines (LPCs) and total steroids. Compared with EFV, RPV increased metabolites with anti-inflammatory properties and reduced the repository of specific lipotoxic lipids.

Thematic Areas: Medicine, general & internal Medicine (miscellaneous) Medicine (all)

licence for use: https://creativecommons.org/licenses/by/3.0/es/

Author's mail: joaquim.peraire@urv.cat

Author identifier: 0000-0001-7808-5479

Record's date: 2023-02-22

Papper version: info:eu-repo/semantics/publishedVersion

Link to the original source: https://www.mdpi.com/2077-0383/9/5/1246

Licence document URL: http://repositori.urv.cat/ca/proteccio-de-dades/

Papper original source: Journal Of Clinical Medicine. 9 (5):

APA: Curran A; Rull A; Navarro J; Vidal-González J; Martin-Castillo M; Burgos J; Falcó V; Ribera E; Torrella A; Planas B; Peraire J; Crespo M (2020). Lipidomics Reveals Reduced Inflammatory Lipid Species and Storage Lipids after Switching from EFV/FTC/TDF to RPV/FTC/TDF: A Randomized Open-Label Trial. Journal Of Clinical Medicine, 9(5), -. DOI: 10.3390/jcm9051246

Article's DOI: 10.3390/jcm9051246

Entity: Universitat Rovira i Virgili

Journal publication year: 2020

Publication Type: Journal Publications